查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840819

肝病診斷市場按產品、疾病類型和最終用戶分類 - 全球預測（2025-2032 年）

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝病診斷市場規模將達到 275.7 億美元，複合年成長率為 9.42%。

關鍵市場統計數據
基準年 2024 134.1億美元
預計年份：2025年 146億美元
預測年份 2032 275.7億美元
複合年成長率 (%) 9.42%

全面說明不斷變化的診斷格局，其中臨床緊迫性、技術創新和政策正在重塑肝病檢測和治療路徑。

開篇部分將讀者置於一個快速發展的診斷生態系統中，在這個系統中，技術創新、臨床需求和監管變革正在交匯融合，重新定義肝臟疾病的檢測、分期和監測方式。非侵入性檢測技術的進步、成像解析度的提高以及更靈敏的血液標記物的出現正在重塑臨床路徑，而醫療系統則在尋求能夠縮短診斷時間並支持以價值為導向的醫療服務的診斷方法。因此，臨床、商業和政策領域的相關人員必須重新評估傳統方法，並考慮採用與現代醫療模式相契合的綜合診斷演算法。

本導言概述了推動變革的核心力量，為後續的論述組裝了基礎：臨床醫生對可操作資訊的需求、患者對微創治療方案的偏好，以及支付方對醫療效率和療效的關注。此外，本導言也著重闡述了傳統組織病理學與新興技術之間的相互作用，並強調了策略規劃、跨學科合作以及對實證醫學投入的重要性，以加速技術應用並最佳化臨床效用。

技術創新、臨床重點以及不斷變化的監管和報銷壓力將如何改變肝病診斷的交付模式

在技​​術、臨床和商業性層面，肝病診斷格局正經歷著多項變革性的轉變。在技​​術層面，診斷方法正朝著微創或非侵入性方向發展，力求在確保診斷準確性的同時兼顧患者的舒適度，這些方法包括先進的影像技術、增強的實驗室生物標記檢測以及利用計算分析從現有數據流中提取新的訊號。在臨床層面，診斷重點正從偶發性診斷轉向縱向疾病監測，以便早期療育並進行更細緻的風險分層。

從商業性角度來看，診斷技術開發人員、影像供應商和實驗室服務公司之間的夥伴關係正變得更加策略性，旨在提供整合解決方案而非單一產品。法律規範也不斷發展以適應新型診斷技術，而支付方也越來越重視臨床效用和成本效益的證據來做出報銷決策。總而言之，這些變化有利於那些能夠證明其擁有強大的臨床檢驗、能夠無縫整合到醫療服務路徑中，並能為醫療服務提供者和支付方提供清晰價值主張的提案。

預測並管理關稅調整對2025年診斷設備和試劑採購、供應鏈和實施計畫的影響

關稅等政策措施有可能為全球診斷價值鏈帶來新的複雜性，尤其對於在生產和分銷過程中跨境流動的零件和設備而言更是如此。在美國，2025年宣布的關稅調整可能會影響診斷設備、成像硬體和專用試劑的採購經濟效益，迫使製造商重新評估籌資策略，並促使供應商評估其總體擁有成本。此類調整可能會加速供應商整合，促進供應鏈區域化，並鼓勵製造商與醫療系統簽訂長期契約，以穩定需求和價格。

除了採購環節，關稅還可能影響新產品上市的投資時機，因為企業需要權衡在進口動態不斷變化的市場中推出新產品的商業性可行性。服務提供者和診斷實驗室可能會透過加強與本地製造商的夥伴關係或增加庫存緩衝來應對短期價格波動。此外，資本密集影像升級的延遲可能會影響先進技術融入常規診療的速度，進而影響臨床應用率。因此，制定一項結合供應鏈多元化、合約對沖以及向支付方證明價值的策略應對措施，對於減輕關稅相關干擾的累積影響至關重要。

主導深度細分，將產品類型、疾病特異性診斷需求和最終用戶工作流程連結起來，從而指導產品和臨床策略。

市場區隔揭示了診斷創新技術的整合方向以及臨床工作流程與產品功能之間的相互作用。在按產品進行市場細分時，切片檢查技術仍然是組織切片檢查的基礎，其中腹腔鏡、經皮和靜脈切片檢查切片檢查針對不同的臨床場景，滿足不同的安全性要求和採樣需求。雖然以丙胺酸轉氨酶、天門冬胺酸轉氨酶和γ-谷氨醯轉肽酶為中心的檢測方法仍是常規操作，但新型多重生物標記正在湧現，以提高特異性並用於長期監測。診斷影像技術，包括電腦斷層掃描、MRI和超音波，也在不斷發展，採用更高解析度、功能性影像序列和基於軟體的定量分析技術，從而增強臨床醫生的解讀能力。

依疾病類型細分，可以更清楚地展現急性肝炎、酒精性肝病、慢性肝炎、肝硬化、肝細胞癌和非酒精性脂肪性肝病的需求模式和臨床需求，每種疾病都對應著獨特的檢測策略和後續治療方案。診斷實驗室最佳化高通量分析和檢測方法驗證；醫院將多模態診斷整合到病患診療路徑和流程中；研究機構則致力於生物標記的發現和臨床檢驗。這些視角能夠細緻地展現臨床需求、技術適用性和應用場景，進而指南產品開發和商業化策略。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和差異化採用模式正在影響策略性市場進入和規模擴張決策。

美洲、歐洲、中東和非洲以及亞太地區的肝病診斷需求和創新路徑正受到區域動態的影響，每個地區都有其獨特的考量。在美洲，人們高度重視臨床可擴展性和診斷技術與大型醫療保健系統的整合，強大的腫瘤學和肝病學研究網路推動了先進影像學和分子檢測技術的早期應用。該地區的醫療保健系統也傾向於優先考慮能夠獎勵已證實的臨床和經濟價值的報銷模式，這影響著新診斷技術的定位和應用。

歐洲、中東和非洲地區（EMEA）的法規環境和醫療基礎設施各不相同，導致產品採納率和打入市場策略也存在差異。擁有集中式衛生技術評估流程的國家需要強力的臨床證據，而尋求實用且經濟高效的解決方案的國家則採納速度更快。在亞太地區，對診斷能力的快速投資、非酒精性脂肪肝疾病負擔的日益加重以及診斷產品生產能力的不斷擴大，正在推動國內創新和出口導向生產。在所有地區，跨境合作、監管協調以及對當地臨床工作流程的考量，對於產品的成功引進和規模化生產仍然至關重要。

儀器製造商、檢測技術創新者、實驗室網路和靈活的新興企業之間的競爭行動和策略夥伴關係正在決定該行業的未來發展軌跡。

肝病診斷領域的企業活動涵蓋了成熟的設備製造商、專業的檢測方法開發商、臨床實驗室網路以及專注於利基生物標記創新的敏捷型新興企業。現有的影像設備製造商和供應商不斷利用裝置量和服務關係，推出軟體增強功能；而專業的檢測方法開發人員則致力於開展臨床檢驗研究並獲得關鍵法規核准，以推動產品從研究用途走向臨床應用。臨床實驗室則著重標準化、高通量以及與電子健康記錄的整合，以從常規篩檢和監測方案中取得檢測量。

合作開發模式日益普及，檢測技術創新者與實驗室網路和影像供應商合作，達成共同開發契約，提供聯合診斷服務。將臨床檢驗工作與支付方合作結合的策略聯盟，能夠加速報銷談判和實際應用。同時，規模較小的公司通常瞄準臨床細分領域，例如非侵入性纖維化評估或早期腫瘤檢測，在擴大商業性版圖之前先確立其臨床效用。那些優先考慮互通性、嚴謹的證據生成和可擴展生產的製造商，更有可能在競爭和監管壓力下保持成長。

這是一份切實可行的策略指南，旨在幫助診斷技術開發人員和醫療保健領導者加速臨床應用、最佳化供應鏈彈性並確保報銷機制的協調一致。

產業領導者若想在肝病診斷領域維持並擴大市場佔有率，應將商業策略與臨床證據的產生和切實可行的部署計畫結合。優先進行嚴謹的前瞻性研究，以證明其在真實世界中的臨床效用，有助於加強醫保報銷談判，並提升臨床醫師的信心。同時，透過與電子健康記錄的無縫連接、標準化的報告格式以及決策支援演算法，將診斷結果整合到診療路徑中，可以減少臨床工作流程中的摩擦，並提高診斷技術的採納率。

在營運方面，供應鏈多元化、尋求區域製造夥伴關係以及建立長期採購協議可以降低關稅波動帶來的風險。研發團隊還應制定分階段的市場進入計劃，充分考慮當地的監管環境和支付方，並利用試點項目和當地意見領袖來推動市場發展。最後，與醫院、診斷實驗室和研究機構建立合作關係，有助於收集產品迭代所需的證據，並促進產品在臨床上的廣泛應用。

一種透明的、專家主導的調查方法，結合了相關人員訪談、臨床指南一致性以及交叉檢驗的證據綜合，以得出可操作的結論。

調查方法融合了定性和定量方法，以確保研究結果的穩健性、可重複性和臨床有效性。主要資料收集包括對臨床醫生、實驗室主任和行業高管進行結構化訪談，以了解實踐模式、未滿足的需求和實施障礙。專家意見與二級資訊來源（包括同行評審文獻、監管文件和臨床指南）進行三角驗證，以檢驗臨床結論並在標準治療框架內解讀新興技術。

我們的分析流程強調透過證據綜合，對多個資訊流進行交叉檢驗，重點在於臨床效用、整合可行性和商業化準備。細分和映射將產品、疾病類型和最終用戶背景進行匹配，以反映實際部署場景。我們的品質保證流程包括專家評審週期，以及透明地說明納入標準、資料來源和假設的調查方法和資料來源。對於新興技術，特別是那些缺乏長期結果數據的技術，我們會根據現有依證提出建議，同時承認其局限性，並指出需要進一步檢驗的領域。

本文綜合闡述了各項策略要務，展現了實證創新、整合工作流程和彈性運作將如何決定肝病診斷領域未來的領導地位。

分析結果表明，肝病診斷領域正處於曲折點，技術進步、臨床對微創檢測的需求以及醫療保險報銷政策的轉變，共同創造了重要的策略機會。能夠展現清晰的臨床效用、無縫融入醫療服務提供者的工作流程並有效管理供應鏈和政策風險的公司，將佔據主要企業。同時，採取務實方法進行檢驗和整合的醫療系統和實驗室，也將從病患診療路徑和營運效率的提升中獲益。

未來，最具變革性的益處將來自於能夠實現早期檢測、更精準分期和縱向監測以指導治療方案選擇的診斷解決方案。要實現這一潛力，需要持續投資於臨床證據、合作商業化模式以及能夠應對區域和政策動態的適應性營運策略。積極進行跨夥伴關係並優先考慮以患者為中心的結果的相關人員，最有能力將診斷創新轉化為更好的臨床實踐和更佳的健康結果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將非侵入性液態生物檢體整合到常規肝病診斷通訊協定中，而不是進行影像學檢查。
  • 推出一款由人工智慧驅動的影像分析工具，用於早期檢測肝纖維化和脂肪肝
  • 擴展多標靶生物標記組合，以全面評估肝臟發炎和纖維化分期
  • 在基層醫療機構應用照護現場瞬時彈性成像設備監測慢性肝病進展
  • 開發可攜式生物感測器平台，用於門診患者肝功能生物標記的即時監測

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肝病診斷市場（依產品類型分類）

  • 切片檢查技術
    • 切片檢查肝臟切片
    • 經皮肝經皮切片檢查
    • 靜脈肝切片檢查
  • 血液檢查
    • 丙氨酸轉氨酶試驗
    • 天門冬胺酸轉氨酶試驗
    • γ-谷氨醯轉肽酶試驗
  • 內視鏡檢查
  • 影像診斷
    • 電腦斷層掃描
    • MRI
    • 超音波

第9章 肝病診斷市場（依疾病類型分類）

  • 急性肝炎
  • 酒精性肝臟疾病
  • 慢性肝炎
  • 肝硬化
  • 肝細胞癌
  • 非酒精脂肪肝

第10章 肝病診斷市場（依最終用戶分類）

  • 診斷實驗室
  • 醫院
  • 研究所

第11章 各地區肝病診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 肝病診斷市場（依組別分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國肝病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Amgen Inc.
    • Argon Medical Devices, Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Boston Scientific Corporation
    • Cook Medical Incorporated
    • Echosens by Astor Partners Srl
    • Epigenomics AG
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • Hepatiq, Inc.
    • Hologic, Inc.
    • Horiba, Ltd.
    • Koninklijke Philips NV
    • Laboratory Corporation of America Holdings
    • Medtronic PLC
    • Merck & Co., Inc.
    • Perspectum Ltd.
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • Randox Laboratories Ltd.
    • Ri.Mos. Srl
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc.
Product Code: MRR-B9334AD6C587

The Liver Disease Diagnostics Market is projected to grow by USD 27.57 billion at a CAGR of 9.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.41 billion
Estimated Year [2025] USD 14.60 billion
Forecast Year [2032] USD 27.57 billion
CAGR (%) 9.42%

A comprehensive orientation to the evolving diagnostic landscape where clinical urgency, innovation, and policy are reshaping liver disease detection and care pathways

The opening section situates the reader in a rapidly evolving diagnostic ecosystem where technological innovation, clinical need, and regulatory change are converging to redefine how liver disease is detected, staged, and monitored. Advances in non-invasive testing, improvements in imaging resolution, and more sensitive blood-based markers are reshaping clinical pathways, while health systems seek diagnostics that reduce time-to-diagnosis and support value-based care. As a result, stakeholders across clinical, commercial, and policy domains must reassess legacy approaches and consider integrated diagnostic algorithms that align with contemporary care models.

This introduction frames the broader narrative by outlining the central forces driving change: clinician demand for actionable information, patient preference for less invasive options, and payer emphasis on care efficiency and outcomes. It highlights the interplay between traditional histopathology and emerging modalities, and sets expectations for the analysis that follows by underscoring the need for strategic planning, cross-disciplinary collaboration, and investment in evidence generation to accelerate adoption and optimize clinical utility.

How technological innovation, clinical priorities, and evolving regulatory and reimbursement pressures are jointly transforming liver disease diagnostics delivery models

Several transformative shifts are redefining the liver disease diagnostics landscape, spanning technological, clinical, and commercial dimensions. On the technological front, there is a pronounced move toward minimally invasive or non-invasive modalities that balance diagnostic accuracy with patient comfort, including refined imaging, enhanced lab-based biomarkers, and computational analytics that extract new signal from established data streams. Clinically, the emphasis is shifting from episodic diagnosis to longitudinal disease monitoring, enabling earlier intervention and more nuanced risk stratification.

From a commercial perspective, partnerships between diagnostic developers, imaging vendors, and laboratory services are becoming more strategic, aimed at delivering integrated solutions rather than point products. Regulatory frameworks are evolving to accommodate novel diagnostics, and payers are increasingly focused on evidence of clinical utility and cost-effectiveness to inform reimbursement decisions. Taken together, these shifts favor companies that can demonstrate robust clinical validation, seamless integration into care pathways, and clear value propositions for providers and payers.

Anticipating and managing the ripple effects of 2025 tariff adjustments on procurement, supply chains, and adoption timelines for diagnostic devices and reagents

Policy actions like tariffs can introduce new complexities into the global diagnostics value chain, particularly for components and instruments that travel across borders during manufacturing and distribution. In the United States, tariff changes announced in 2025 have the potential to influence procurement economics for diagnostic equipment, imaging hardware, and specialized reagents, creating pressure on manufacturers to reassess sourcing strategies and on providers to evaluate total cost of ownership. These adjustments may accelerate supplier consolidation, regionalize supply chains, and prompt manufacturers to negotiate long-term contracts with health systems to stabilize demand and pricing.

Beyond procurement, tariffs can affect investment timing for new product introductions, as companies weigh the commercial viability of launches in markets with altered import dynamics. Service providers and diagnostic laboratories may respond by intensifying local manufacturing partnerships or increasing inventory buffers to manage short-term pricing volatility. In addition, the ripple effects can influence clinical adoption rates where capital-intensive imaging upgrades are deferred, thereby shaping the pace at which advanced modalities diffuse into routine practice. Strategic responses that combine supply-chain diversification, contractual hedging, and value demonstration to payers will be critical to mitigating the cumulative impact of tariff-related disruption.

Deep segmentation-driven insights that connect offering types, disease-specific diagnostic needs, and end-user workflows to guide product and clinical strategy

Segmentation illuminates where diagnostic innovation is concentrated and how clinical workflows interact with product capabilities. When the market is parsed by offering, biopsy techniques remain foundational for definitive tissue diagnosis, with laparoscopic liver biopsy, percutaneous liver biopsy, and transvenous liver biopsy each serving distinct clinical scenarios tied to safety profile and sampling needs. Concurrently, blood-based tests are advancing beyond basic hepatic panels: assays centered on alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase continue to be routine, while multiplexed and novel biomarkers are emerging to improve specificity and longitudinal monitoring. Imaging diagnostics-spanning CT scan, MRI, and ultrasound-are evolving through enhanced resolution, functional imaging sequences, and software-driven quantification that augment clinician interpretation.

Disease-type segmentation further clarifies demand patterns and clinical imperatives across acute hepatitis, alcoholic liver disease, chronic hepatitis, cirrhosis, hepatocellular carcinoma, and non-alcoholic fatty liver disease, each driving distinct testing strategies and follow-up regimens. End-user segmentation identifies where innovation is operationalized: diagnostic laboratories optimize high-throughput analytics and assay validation; hospitals integrate multimodal diagnostics into patient pathways and procedural workflows; and research institutes advance biomarker discovery and clinical validation. Together, these lenses provide a granular view of clinical need, technology fit, and deployment contexts that should guide product development and commercialization strategies.

Regional dynamics and differentiated adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape strategic market entry and scale-up decisions

Regional dynamics shape both demand and innovation pathways in liver disease diagnostics, with distinct considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical practice emphasizes scalability and integration of diagnostics into large health systems, with strong oncology and hepatology research networks driving early adoption of advanced imaging and molecular assays. Health systems in this region also tend to prioritize reimbursement models that reward demonstrable clinical and economic value, influencing how new diagnostics are positioned and adopted.

The Europe, Middle East & Africa region exhibits heterogeneity in regulatory environments and healthcare infrastructure, which creates a patchwork of adoption rates and market access strategies. Countries with centralized health technology assessment processes demand robust clinical evidence, while others exhibit faster uptake for pragmatic, cost-effective solutions. In Asia-Pacific, rapid investment in diagnostic capacity, growing burden of non-alcoholic fatty liver disease, and expanding diagnostic manufacturing capabilities are catalyzing both domestic innovation and export-oriented production. Across all regions, cross-border collaboration, regulatory harmonization, and attention to localized clinical workflows remain essential for successful product introduction and scale-up.

Competitive behaviors and strategic partnerships among instrument makers, assay innovators, laboratory networks, and nimble startups that are defining industry trajectories

Company behavior in the liver disease diagnostics space is being shaped by a mix of established instrument manufacturers, specialized assay developers, clinical laboratory networks, and nimble start-ups focused on niche biomarker innovations. Incumbent imaging and instrument providers continue to leverage installed bases and service relationships to introduce software-enabled enhancements, while specialized assay developers pursue clinical validation studies and key regulatory clearances to move from research use to clinical adoption. Clinical laboratory operators emphasize standardization, throughput, and integration with electronic medical records to capture volume from routine screening and monitoring protocols.

Collaborative models are increasingly prevalent, with partnerships and co-development agreements linking assay innovators to lab networks or imaging vendors to create combined diagnostic offerings. Strategic alliances that align clinical validation efforts with payer engagement accelerate reimbursement conversations and practical adoption. Meanwhile, smaller companies often pursue targeted clinical niches-such as non-invasive fibrosis assessment or early tumor detection-to establish clinical utility before broadening their commercial footprint. Manufacturers that prioritize interoperability, rigorous evidence generation, and scalable manufacturing will be best positioned to sustain growth amid competitive and regulatory pressures.

Actionable strategic playbook for diagnostic developers and healthcare leaders to accelerate clinical adoption, optimize supply resilience, and secure reimbursement alignment

Industry leaders seeking to maintain or grow their presence in liver disease diagnostics should align commercial strategy with clinical evidence generation and pragmatic deployment plans. Prioritizing rigorous prospective studies that demonstrate clinical utility in real-world settings will strengthen reimbursement discussions and clinician confidence. At the same time, integrating diagnostic outputs into care pathways-through seamless electronic health record connectivity, standardized reporting formats, and decision-support algorithms-will increase adoption by reducing friction in clinical workflows.

From an operational perspective, diversifying supply chains, pursuing regional manufacturing partnerships, and cultivating long-term procurement agreements can mitigate exposure to tariff-induced volatility. Commercial teams should also develop tiered market entry plans that account for regional regulatory variance and payer landscapes, leveraging pilot deployments and local opinion leaders to build momentum. Finally, cultivating collaborative relationships with hospitals, diagnostic laboratories, and research institutions enables iterative product refinement and supports the evidence generation needed to sustain broad clinical uptake.

A transparent, expert-driven methodology combining stakeholder interviews, clinical guideline alignment, and cross-validated evidence synthesis to underpin actionable conclusions

The research methodology integrates qualitative and quantitative approaches to ensure findings are robust, reproducible, and clinically relevant. Primary data collection includes structured interviews with clinicians, laboratory directors, and industry executives to capture practice patterns, unmet needs, and adoption barriers. Expert advisory input is triangulated with secondary sources, including peer-reviewed literature, regulatory filings, and clinical guidelines, to validate clinical claims and interpret emerging technologies within standard-of-care frameworks.

Analytical procedures emphasize cross-validation across multiple information streams, with evidence synthesis focused on clinical utility, integration feasibility, and commercialization readiness. Segmentation mapping aligns offerings, disease types, and end-user contexts to reflect real-world deployment scenarios. Quality assurance processes include expert review cycles and methodological documentation that transparently describe inclusion criteria, data sources, and assumptions. Limitations are acknowledged, particularly where nascent technologies lack long-term outcome data, and recommendations are framed to reflect the current evidence base while identifying areas where further validation is needed.

Synthesis of strategic imperatives showing how evidence-driven innovation, integrated workflows, and resilient operations will determine future leadership in liver disease diagnostics

This analysis concludes that the liver disease diagnostics landscape is at an inflection point where technological progress, clinical demand for less invasive testing, and shifting reimbursement priorities converge to create significant strategic opportunities. Companies that can demonstrate clear clinical utility, integrate seamlessly into provider workflows, and manage supply-chain and policy risks will be positioned to lead. At the same time, health systems and laboratories that adopt a pragmatic approach to validation and integration will realize benefits in patient care pathways and operational efficiency.

Looking forward, the most transformative gains will arise from diagnostic solutions that enable earlier detection, more precise disease staging, and longitudinal monitoring that informs treatment choices. Realizing this potential requires sustained investment in clinical evidence, collaborative commercialization models, and adaptive operational strategies that respond to regional and policy dynamics. Stakeholders who embrace cross-sector partnerships and prioritize patient-centered outcomes will be best placed to translate diagnostic innovation into improved clinical practice and health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of noninvasive liquid biopsy assays into routine liver disease diagnostic protocols over imaging
  • 5.2. Implementation of AI-driven image analysis tools for early detection of hepatic fibrosis and steatosis
  • 5.3. Expansion of multitarget biomarker panels for comprehensive assessment of liver inflammation and fibrosis staging
  • 5.4. Adoption of point-of-care transient elastography devices in primary care settings to monitor chronic liver disease progression
  • 5.5. Development of portable biosensor platforms for real-time monitoring of liver function biomarkers in outpatient clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Disease Diagnostics Market, by Offering

  • 8.1. Biopsy Techniques
    • 8.1.1. Laparoscopic Liver Biopsy
    • 8.1.2. Percutaneous Liver Biopsy
    • 8.1.3. Transvenous Liver Biopsy
  • 8.2. Blood-Based Tests
    • 8.2.1. Alanine Transaminase Test
    • 8.2.2. Aspartate Transaminase Test
    • 8.2.3. Gamma-Glutamyl Transpeptidase Test
  • 8.3. Endoscopy
  • 8.4. Imaging Diagnostics
    • 8.4.1. CT Scan
    • 8.4.2. MRI
    • 8.4.3. Ultrasound

9. Liver Disease Diagnostics Market, by Disease Type

  • 9.1. Acute Hepatitis
  • 9.2. Alcoholic Liver Disease
  • 9.3. Chronic Hepatitis
  • 9.4. Cirrhosis
  • 9.5. Hepatocellular Carcinoma
  • 9.6. Non-Alcoholic Fatty Liver Disease

10. Liver Disease Diagnostics Market, by End-User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Liver Disease Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Liver Disease Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Liver Disease Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Abbott Laboratories
    • 14.3.2. Amgen Inc.
    • 14.3.3. Argon Medical Devices, Inc.
    • 14.3.4. Bayer AG
    • 14.3.5. Becton, Dickinson and Company
    • 14.3.6. Bio-Rad Laboratories, Inc.
    • 14.3.7. BioMerieux SA
    • 14.3.8. Boston Scientific Corporation
    • 14.3.9. Cook Medical Incorporated
    • 14.3.10. Echosens by Astor Partners S.r.l.
    • 14.3.11. Epigenomics AG
    • 14.3.12. F. Hoffmann-La Roche Ltd.
    • 14.3.13. Fujifilm Holdings Corporation
    • 14.3.14. Hepatiq, Inc.
    • 14.3.15. Hologic, Inc.
    • 14.3.16. Horiba, Ltd.
    • 14.3.17. Koninklijke Philips N.V.
    • 14.3.18. Laboratory Corporation of America Holdings
    • 14.3.19. Medtronic PLC
    • 14.3.20. Merck & Co., Inc.
    • 14.3.21. Perspectum Ltd.
    • 14.3.22. Qiagen N.V.
    • 14.3.23. Quest Diagnostics Incorporated
    • 14.3.24. Randox Laboratories Ltd.
    • 14.3.25. Ri.Mos. Srl
    • 14.3.26. Siemens Healthineers AG
    • 14.3.27. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 282. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 283. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 284. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 285. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 287. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. E